Literature DB >> 24221219

[Therapy of recurrent and metastatic squamous cell carcinoma of the head and neck : highlights of the ASCO Meeting 2013].

M Hezel1, T Kurzweg, A Münscher, P Schafhausen, R Knecht.   

Abstract

In many cases squamous cell carcinoma of the head and neck is already in an advanced stage when initially diagnosed. Despite definitive treatment, loco-regional recurrences and metastases are common and patients ultimately require systemic treatment. Epidermal growth factor receptor (EGFR) inhibitors have proven to significantly prolong survival and have therefore become the first line treatment in recurrent and metastatic squamous cell carcinoma of the head and neck in addition to platinum and 5-FU treatment. Good results have also been reported for EGFR inhibitors in cases where platinum-based treatment has failed. Further strategies, such as salvage surgery, platinum-based chemotherapy, targeted therapy, chemoradiation and reirradiation are currently under investigation to reduce toxicity and improve survival and health-related quality of life.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24221219     DOI: 10.1007/s00106-013-2768-2

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  5 in total

1.  Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysis.

Authors:  Fausto Petrelli; Sandro Barni
Journal:  Head Neck       Date:  2011-09-23       Impact factor: 3.147

Review 2.  Reirradiation for recurrent head and neck cancer.

Authors:  Pretesh R Patel; Joseph K Salama
Journal:  Expert Rev Anticancer Ther       Date:  2012-09       Impact factor: 4.512

Review 3.  Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.

Authors:  Dong M Shin; Fadlo R Khuri
Journal:  Head Neck       Date:  2011-11-02       Impact factor: 3.147

Review 4.  Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.

Authors:  Ana Markovic; Christine H Chung
Journal:  Expert Rev Anticancer Ther       Date:  2012-09       Impact factor: 4.512

5.  Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.

Authors:  Christopher J Barnes; Kazufumi Ohshiro; Suresh K Rayala; Adel K El-Naggar; Rakesh Kumar
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.